Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Scheres, L, Brekelmans, M, Ageno, W, Ay, C, Büller, HR, Eichinger, S, Hutten, BA, Klok, FA, Middeldorp, S, Schreiber, K, Stach, K, Blondon, M & Delluc, A 2018, 'Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study', BJOG : an international journal of obstetrics and gynaecology, vol. 125, no. 12, pp. 1581-1589. https://doi.org/10.1111/1471-0528.15388

APA

Scheres, L., Brekelmans, M., Ageno, W., Ay, C., Büller, H. R., Eichinger, S., Hutten, B. A., Klok, F. A., Middeldorp, S., Schreiber, K., Stach, K., Blondon, M., & Delluc, A. (2018). Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG : an international journal of obstetrics and gynaecology, 125(12), 1581-1589. https://doi.org/10.1111/1471-0528.15388

CBE

MLA

Vancouver

Author

Scheres, Ljj ; Brekelmans, Mpa ; Ageno, W ; Ay, C ; Büller, H R ; Eichinger, S ; Hutten, B A ; Klok, F A ; Middeldorp, S ; Schreiber, K ; Stach, K ; Blondon, M ; Delluc, A. / Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism : a post hoc analysis of the Hokusai-VTE study. In: BJOG : an international journal of obstetrics and gynaecology. 2018 ; Vol. 125, No. 12. pp. 1581-1589.

Bibtex

@article{954cbc19f86540bba74a961d6000b04d,
title = "Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study",
abstract = "OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE.POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE.METHODS: We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events.MAIN OUTCOME MEASURES: Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events.RESULTS: In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person-years (py) (95% CI 11-19) in women receiving edoxaban and 9/100 py (95% CI 6-12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1-2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8-10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0-2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients.CONCLUSIONS: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome.TWEETABLE ABSTRACT: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.",
author = "Ljj Scheres and Mpa Brekelmans and W Ageno and C Ay and B{\"u}ller, {H R} and S Eichinger and Hutten, {B A} and Klok, {F A} and S Middeldorp and K Schreiber and K Stach and M Blondon and A Delluc",
note = "{\textcopyright} 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.",
year = "2018",
month = nov,
doi = "10.1111/1471-0528.15388",
language = "English",
volume = "125",
pages = "1581--1589",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism

T2 - a post hoc analysis of the Hokusai-VTE study

AU - Scheres, Ljj

AU - Brekelmans, Mpa

AU - Ageno, W

AU - Ay, C

AU - Büller, H R

AU - Eichinger, S

AU - Hutten, B A

AU - Klok, F A

AU - Middeldorp, S

AU - Schreiber, K

AU - Stach, K

AU - Blondon, M

AU - Delluc, A

N1 - © 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

PY - 2018/11

Y1 - 2018/11

N2 - OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE.POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE.METHODS: We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events.MAIN OUTCOME MEASURES: Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events.RESULTS: In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person-years (py) (95% CI 11-19) in women receiving edoxaban and 9/100 py (95% CI 6-12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1-2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8-10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0-2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients.CONCLUSIONS: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome.TWEETABLE ABSTRACT: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.

AB - OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE.POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE.METHODS: We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events.MAIN OUTCOME MEASURES: Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events.RESULTS: In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person-years (py) (95% CI 11-19) in women receiving edoxaban and 9/100 py (95% CI 6-12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1-2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8-10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0-2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients.CONCLUSIONS: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome.TWEETABLE ABSTRACT: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.

U2 - 10.1111/1471-0528.15388

DO - 10.1111/1471-0528.15388

M3 - Journal article

C2 - 29940089

VL - 125

SP - 1581

EP - 1589

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 12

ER -

ID: 56676647